Contact us here!
Contact us for questions, general inquiries, or to request a quote.
By submitting this form, I consent to the processing of my personal data as explained in Ossiform's Privacy Policy.
Contact us for questions, general inquiries, or to request a quote.
By submitting this form, I consent to the processing of my personal data as explained in Ossiform's Privacy Policy.
Transformative research is unpredictable, and the pioneers of such research may not always realize when they are on the cusp of a radical breakthrough. Many research pioneers begin their careers with an insatiable curiosity and drive to address unmet challenges. Indeed, Emerson once said, “Do not go where the path may lead; go where there is no path and leave a trail.”
However, establishing a completely new field or path can be risky. Curiosity-driven, high-risk, high-reward research paths do not guarantee a hit research paper or a tenure-track position. Scientists, especially early-career stage researchers, and their groups must balance low and high-risk projects as they navigate the ‘publish or perish’ culture.
Yet, it may be comforting to acknowledge that transformative findings and breakthroughs are rarely stand-alone events (Gravem et al., 2017). Instead, they are shaped by social, economic, and even remote technological developments, such as additive manufacturing.
Consider for a moment there was a time when radical treatment of bone and joint injuries and diseases was amputation (Gomez et al., 2005). In the pre-anesthesia era of the 1700s and 1800s, the rudimentary procedure was valued for its quickness. From this day forward, however, transformative and state-of-the-art treatment will involve the addition and proliferation rather than the excision of bone.

If transformative research is built on incremental advancements, the evolution of 3D bone printing and today’s biocompatible inks offers a clear example. Only a few decades ago, printing bone-like structures with controlled architecture was still experimental; now, researchers can produce highly reproducible, biologically relevant scaffolds on demand. This pattern mirrors other groundbreaking technologies, such as the CRISPR-Cas9 gene-editing tool, first published quietly in 2012 (Jinek et al., 2012). What began as a technical refinement rapidly became one of the most influential research tools in modern science – accelerating work in genetic disease, agriculture, and drug development. Likewise, 3D bone printing is poised to transition from a promising advancement to a foundational enabler of entirely new research directions.
In another context, replacing the hip joint with an artificial one was once only conceptual. At least until a medical professor, Sir John Charnley, designed and performed the first truly long-lasting replacement in 1962. Since then, the orthopedic procedure total hip arthroplasty (THA) has been the most implemented worldwide. THA and then eventually total knee arthroplasty (TKA) catalyzed an intense and massive research field in its own right (Holzer and Holzer, 2014). The field has become so large that it has already begun evaluating the benefits of 3D bone printing to help prepare for more complex cases of THA (Anzillotti et al., 2024).
Just as new technologies once transformed clinical treatment, emerging tools like 3D bone printing are now transforming how bone research itself is conducted. In the case of 3D bone printing, we expect to see an acceleration of established research paths and the creation of new ones. Both will be underscored by the advantages of experimenting with structures (scaffolds) that mimic the physical properties of natural bone in vitro.
While 2D cell cultures are affordable and straightforward, allowing the study of how bone cells interact, they cannot mimic the complex 3D environment of real bones. Research groups breaking free from traditional petri dish experiments to test their hypotheses stand to benefit the most. That is, the results are more likely to endure a direct in-vitro to in-vivo translation.
Generally, there is a major need to test, develop and improve in-vitro experimental conditions. When that need is met, it can lead to innovative results like the recently developed bone-on-chip (BoC) device. Coupled with the capabilities of 3D bone printing, the BoC device is designed to understand the remodeling process from start to finish (Nasello et al., 2021; Arrigoni et al., 2017). Similar to working with bone scaffolds alone, the BoC device can extend testing drug efficacy and side effects on bone activity, potentially shortening the time to reach therapeutic success. With these capabilities in hand, the question becomes: where will the next breakthroughs come from?

The technology level of 3D bioprinters is generally at a point of maturity where research teams can affordably adopt higher-risk and higher-reward projects. At the same time, 3D printed bone scaffolds eliminate specific risks that would normally weaken translational findings in traditional 2D cell cultures. 3D bone-printing outshines 2D cell cultures by significantly improving:
The P3D Scaffolds from Ossiform® provide researchers with these benefits while still providing a high degree of reproducibility and stability with no batch-to-batch variance.
Still, there are more direct benefits of 3D bone-printing that will underpin transformative research. Part of that transformation will start by replacing the needs and costs and removing the risks of ‘translational failure’ associated with using animal models. That is, the results obtained using animal models often fail to translate in the same way to humans. It is well understood that, for example, drug development is hindered by low animal-to-human success rates (Leenaars et al., 2019) and 3D bone-printing is uniquely positioned to change those statistics.
The true power of 3D bone printing lies not only in the printers themselves, but in the biocompatible inks used to create the scaffolds (Verma et al., 2023). These biomaterials are generally classified into two types: natural and synthetic. Each type has unique characteristics, such as how well they can be printed and their ability to support cell adhesion and growth over time. Also, for a research model, the scaffold must make it easy to identify the material deposited by osteoblasts.
Amongst the most critical parameters for a printed scaffold, as shown for Ossiform’s beta-tricalcium phosphate (β-TCP) formulation, is that it is osteoconductive, resorbable in vivo yet stable in vitro, provides relevant biomechanical strength and stiffness, and does not elicit an immune response (Thygesen et al., 2022).

As research questions grow more complex, the tools supporting them must evolve accordingly. 3D bone printing is no longer a futuristic concept – it is an accessible way to accelerate discoveries today.
At Ossiform®, we know that the path to innovation needs the backing of research grants, and 3D bone printing can provide a competitive edge. Feel free to contact our research team at research@ossiform.com for: